{"id":"NCT01641042","sponsor":"GlaxoSmithKline","briefTitle":"Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-10","primaryCompletion":"2014-10-10","completion":"2015-03-03","firstPosted":"2012-07-16","resultsPosted":"2017-10-18","lastUpdate":"2017-10-18"},"enrollment":86,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]}],"arms":[{"label":"Healthy Group","type":"EXPERIMENTAL"},{"label":"At-risk Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy subjects.","primaryOutcome":{"measure":"Number of Subjects With a Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135 and Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) Antibodies","timeFrame":"One month after the first vaccine dose (at Month 1)","effectByArm":[{"arm":"Nimenrix At-Risk Group","deltaMin":40,"sd":null},{"arm":"Nimenrix Healthy Group","deltaMin":39,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":16,"countries":["United States","Czechia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":43},"commonTop":["Pain","Fatigue","Swelling","Erythema","Headache"]}}